1. Key Insights

2. Hereditary Angioedema (HAE): Epidemiology Overview at a Glance
2.1. Total Patient Share (%) Distribution of HAE in 2017
2.2. Total Patient Share (%) Distribution of HAE in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Hereditary Angioedema (HAE): Disease Overview
6.1. Introduction
6.2. Types of Hereditary Angioedema
6.3. Symptoms
6.4. Clinical Presentation
6.5. Risk Factors
6.6. Pathophysiologic and Immunologic Features of HAE
6.6.1. Mechanisms of Edema Formation
6.6.2. Genetics of HAE
6.7. Diagnosis of Hereditary Angioedema
6.7.1. Laboratory Findings
6.7.2. Prenatal and Postnatal Diagnosis
6.7.3. Delayed Diagnosis of HAE—A Persistent Problem with Serious Consequences

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM
7.3. United States
7.3.1. Assumptions and Rationale
7.3.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in the United States
7.3.3. Type-Specific cases of Hereditary Angioedema in the US
7.3.4. Gender-Specific cases of Hereditary Angioedema in the US
7.3.5. Age-Specific cases of Hereditary Angioedema in the US
7.3.6. Site-specific cases of Hereditary Angioedema in the US
7.4. Europe
7.4.1. Assumptions and Rationale
7.5. Germany
7.5.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Germany
7.5.2. Type-Specific cases of Hereditary Angioedema in Germany
7.5.3. Gender-Specific cases of Hereditary Angioedema in Germany
7.5.4. Age-Specific cases of Hereditary Angioedema in Germany
7.5.5. Site-specific cases of Hereditary Angioedema in Germany
7.6. France
7.6.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in France
7.6.2. Type-Specific cases of Hereditary Angioedema in France
7.6.3. Gender-Specific cases of Hereditary Angioedema in France
7.6.4. Age-Specific cases of Hereditary Angioedema in France
7.6.5. Site-specific cases of Hereditary Angioedema in France
7.7. Italy
7.7.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Italy
7.7.2. Type-Specific cases of Hereditary Angioedema in Italy
7.7.3. Gender-Specific cases of Hereditary Angioedema in Italy
7.7.4. Age-Specific cases of Hereditary Angioedema in Italy
7.7.5. Site-specific cases of Hereditary Angioedema in Italy
7.8. Spain
7.8.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Spain
7.8.2. Type-Specific cases of Hereditary Angioedema in Spain
7.8.3. Gender-Specific cases of Hereditary Angioedema in Spain
7.8.4. Age-Specific cases of Hereditary Angioedema in Spain
7.8.5. Site-specific cases of Hereditary Angioedema in Spain
7.9. UK
7.9.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in the UK
7.9.2. Type-Specific cases of Hereditary Angioedema in the UK
7.9.3. Gender-Specific cases of Hereditary Angioedema in the UK
7.9.4. Age-Specific cases of Hereditary Angioedema in the UK
7.9.5. Site-specific cases of Hereditary Angioedema in the UK
7.10. Japan
7.10.1. Assumptions and Rationale
7.10.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in Japan
7.10.3. Type-Specific cases of Hereditary Angioedema in Japan
7.10.4. Gender-specific cases of Hereditary Angioedema in Japan
7.10.5. Age-specific cases of Hereditary Angioedema in Japan
7.10.6. Site-specific cases of Hereditary Angioedema in Japan

8. Treatment of Hereditary Angioedema
8.1. On-demand treatment
8.2. Prophylactic treatment
8.3. Home therapy and self-administration
8.4. WAO Guideline for the Management of Hereditary Angioedema
8.5. Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research
8.6. AAAAI Allergy and Asthma Medication Guide
8.7. The International Hereditary Angioedema Guideline

9. Unmet Needs

10. Case studies
10.1. Hereditary angioedema (HAE): a cause for recurrent abdominal pain
10.2. Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain
10.3. Hereditary angioedema type I in a female patient: a case report

11. KOL Views

12. Bibliography

13. Appendix
13.1. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables
Table 1: A Comprehensive Table of Hereditary Angioedema Types
Table 2: A Comprehensive Table of Hereditary Angioedema Types
Table 3: Summary of the mutations described in F12, plasminogen (PLG), and angiopoietin (ANGPT1) genes resulting in HAE.
Table 4: Total diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017–2030)
Table 5: Total Diagnosed Prevalent Population of Hereditary angioedema in the US (2017–2030)
Table 6: Type-Specific cases of Hereditary Angioedema in the US (2017–2030)
Table 7: Gender-Specific cases of Hereditary Angioedema in the US (2017–2030)
Table 8: Age-Specific cases of Hereditary Angioedema in the US (2017–2030)
Table 9: Site-specific cases of Hereditary Angioedema in the US (2017–2030)
Table 10: Total Diagnosed Prevalent Population of Hereditary angioedema in Germany (2017–2030)
Table 11: Type-Specific cases of Hereditary Angioedema in Germany (2017–2030)
Table 12: Gender-Specific cases of Hereditary Angioedema in Germany (2017–2030)
Table 13: Age-Specific cases of Hereditary Angioedema in Germany (2017–2030)
Table 14: Site-specific cases of Hereditary Angioedema in Germany (2017–2030)
Table 15: Total Diagnosed Prevalent Population of Hereditary angioedema in France (2017–2030)
Table 16: Type-Specific cases of Hereditary Angioedema in France (2017–2030)
Table 17: Gender-Specific cases of Hereditary Angioedema in France (2017–2030)
Table 18: Age-Specific cases of Hereditary Angioedema in France (2017–2030)
Table 19: Site-specific cases of Hereditary Angioedema in France (2017–2030)
Table 20: Total Diagnosed Prevalent Population of Hereditary angioedema in Italy (2017–2030)
Table 21: Type-Specific cases of Hereditary Angioedema in Italy (2017–2030)
Table 22: Gender-Specific cases of Hereditary Angioedema in Italy (2017–2030)
Table 23: Age-Specific cases of Hereditary Angioedema in Italy (2017–2030)
Table 24: Site-specific cases of Hereditary Angioedema in Italy (2017–2030)
Table 25: Total Diagnosed Prevalent Population of Hereditary angioedema in Spain (2017–2030)
Table 26: Type-Specific cases of Hereditary Angioedema in Spain (2017–2030)
Table 27: Gender-Specific cases of Hereditary Angioedema in Spain (2017–2030)
Table 28: Age-Specific cases of Hereditary Angioedema in Spain (2017–2030)
Table 29: Site-specific cases of Hereditary Angioedema in Spain (2017–2030)
Table 30: Total Diagnosed Prevalent Population of Hereditary angioedema in the UK (2017–2030)
Table 31: Type-Specific cases of Hereditary Angioedema in the UK (2017–2030)
Table 32: Gender-Specific cases of Hereditary Angioedema in the UK (2017–2030)
Table 33: Age-Specific cases of Hereditary Angioedema in the UK (2017–2030)
Table 34: Site-specific cases of Hereditary Angioedema in the UK (2017–2030)
Table 35: Total Diagnosed Prevalent Population of Hereditary angioedema in Japan (2017–2030)
Table 36: Type-specific cases of Hereditary Angioedema in Japan (2017–2030)
Table 37: Gender-specific cases of Hereditary Angioedema in Japan (2017–2030)
Table 38: Age-specific cases of Hereditary Angioedema in Japan (2017–2030)

List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Risk Factors of Hereditary Angioedema
Figure 3: C1 esterase inhibitor prevents the autoactivation of complement C1
Figure 4: C1 esterase inhibitor inactivates factors XIIa and XIIf, plasmin, and kallikrein
Figure 5: C1 esterase inhibitor modulates complement and contact system activation
Figure 6: Mechanism of activation of the contact system
Figure 7: Dysregulation of Coagulation, Complement, and Contact Cascades in Hereditary Angioedema
Figure 8: Kinin metabolism and the mutual interactions between the kinin, complement, hemostatic and fibrinolytic pathways
Figure 9: Summary of the genetic defects leading to the phenotype of hereditary angioedema
Figure 10: Various mutations reported in the SERPING1 gene
Figure 11: Counteracting influences of angiopoietin 1 and bradykinin on vascular endothelial cells
Figure 12: Diagnostic Algorithm for Hereditary Angioedema
Figure 13: A proposed diagnostic algorithm for evaluation of a suspected case of hereditary angioedema (HAE with normal C1 inhibitor function requires genetic analysis for diagnosis)
Figure 14: Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017–2030)
Figure 15: Total Diagnosed Prevalence of Hereditary angioedema in the US (2017–2030)
Figure 16: Type-Specific cases of Hereditary Angioedema in the US (2017–2030)
Figure 17: Gender-Specific cases of Hereditary angioedema in the US (2017–2030)
Figure 18: Age-Specific cases of Hereditary Angioedema in the US (2017–2030)
Figure 19: Site-specific cases of Hereditary Angioedema in the US (2017–2030)
Figure 20: Total Diagnosed Prevalence of Hereditary angioedema in Germany (2017–2030)
Figure 21: Type-Specific cases of Hereditary Angioedema in Germany (2017–2030)
Figure 22: Gender-Specific cases of Hereditary angioedema in Germany (2017–2030)
Figure 23: Age-Specific cases of Hereditary Angioedema in Germany (2017–2030)
Figure 24: Site-specific cases of Hereditary Angioedema in Germany (2017–2030)
Figure 25: Total Diagnosed Prevalence of Hereditary angioedema in France (2017–2030)
Figure 26: Type-Specific cases of Hereditary Angioedema in France (2017–2030)
Figure 27: Gender-Specific cases of Hereditary angioedema in France (2017–2030)
Figure 28: Age-Specific cases of Hereditary Angioedema in France (2017–2030)
Figure 29: Site-specific cases of Hereditary Angioedema in France (2017–2030)
Figure 30: Total Diagnosed Prevalence of Hereditary angioedema in Italy (2017–2030)
Figure 31: Type-Specific cases of Hereditary Angioedema in Italy (2017–2030)
Figure 32: Gender-Specific cases of Hereditary angioedema in Italy (2017–2030)
Figure 33: Age-Specific cases of Hereditary Angioedema in Italy (2017–2030)
Figure 34: Site-specific cases of Hereditary Angioedema in Italy (2017–2030)
Figure 35: Total Diagnosed Prevalence of Hereditary angioedema in Spain (2017–2030)
Figure 36: Type-Specific cases of Hereditary Angioedema in Spain (2017–2030)
Figure 37: Gender-Specific cases of Hereditary angioedema in Spain (2017–2030)
Figure 38: Age-Specific cases of Hereditary Angioedema in Spain (2017–2030)
Figure 39: Site-specific cases of Hereditary Angioedema in Spain (2017–2030)
Figure 40: Total Diagnosed Prevalence of Hereditary angioedema in the UK (2017–2030)
Figure 41: Type-Specific cases of Hereditary Angioedema in the UK (2017–2030)
Figure 42: Gender-Specific cases of Hereditary angioedema in the UK (2017–2030)
Figure 43: Age-Specific cases of Hereditary Angioedema in the UK (2017–2030)
Figure 44: Site-specific cases of Hereditary Angioedema in the UK (2017–2030)
Figure 45: Total Diagnosed Prevalence of Hereditary angioedema in Japan (2017–2030)
Figure 46: Type-specific cases of Hereditary Angioedema in Japan (2017–2030)
Figure 47: Gender-specific cases of Hereditary angioedema in Japan (2017–2030)
Figure 48: Age-specific cases of Hereditary Angioedema in Japan (2017–2030)
Figure 49: Site-specific cases of Hereditary Angioedema in Japan (2017–2030)
Figure 50: Unmet Needs